[The value of the cytocins and the solubility of theirs receptors in the serum of the patients with the cervical cancer].
The study encompassed 146 women with recognized invasive cervical cancer in 4 clinical stages. Patients underwent therapy in Oncologic Gynaecology Department of Wrocław Medical University in 2001 and 2002 years. The correlation between pretreatment serum level of proangiogenic and inflammation factors--VEGF, sTNF-R1, IL-6 and clinical stage or early effects of therapy were observed. The strong and statistically significant relationship between pretreatment serum level of IL-6 and sTNF-R1 and clinical stage with early effect of treatment were found. The statistically significant correlation between serum level of all investigated parameters and clinical stage of cervix cancer was noticed. VEGF wasn't an independent prognostic factor in the study, but the prognostic value of IL-6 was demonstrated.
Rusiecka
Małgorzata
M
Katedra Onkologii i Klinika Onkologii Ginekologicznej Akademii Medycznej we Wrocławiu. maru2007@tlen.pl
Sedlaczek
Paweł
P
Rusiecki
Lesław
L
Stepień
Marcin
M
Harłozińska-Szmyrka
Antonina
A
Kornafel
Jan
J
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000097:blood; D016022:Case-Control Studies; D018450:Disease Progression; D005260:Female; D006801:Humans; D015850:Interleukin-6 / Q000097:blood*; D053208:Kaplan-Meier Estimate; D008875:Middle Aged; D009367:Neoplasm Staging; D011044:Poland; D011379:Prognosis; D047888:Receptors, Tumor Necrosis Factor, Type I / Q000097:blood*; D012189:Retrospective Studies; D016896:Treatment Outcome; D002583:Uterine Cervical Neoplasms / Q000097:blood* / Q000473:pathology* / Q000628:therapy; D042461:Vascular Endothelial Growth Factor A / Q000097:blood*
D014408:Biomarkers, Tumor; D015850:Interleukin-6; D047888:Receptors, Tumor Necrosis Factor, Type I; D042461:Vascular Endothelial Growth Factor A